EUVIMEDEUVIMED entdecken
Open Access

Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis

Hongxue Shi iD, Xiaobo Wang iD, Christopher Sloas iD, Brennan Gerlach iD, Arif Yurdagul, Mary P Moore, Eui Jung Jung iD, Faridoddin Mirshahi iD, Luisa Ronzoni iD, Arun J Sanyal, Luca Valenti iD, Chyuan-Sheng Lin iD und 4 weitere

Science Translational Medicine · 10.09.2025 · 17 (815)

DOI: 10.1126/scitranslmed.adv2106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 10.09.2025. Verfasst von Hongxue Shi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Macrophages, Fatty Liver, Liver. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocyte apoptosis is a key feature of metabolic dysfunction–associated steatohepatitis (MASH), but the fate of apoptotic hepatocytes in MASH is poorly understood. Here, we explore the hypotheses that clearance of dead hepatocytes by liver macrophages (efferocytosis) is impaired in MASH because of low expression of the efferocytosis receptor T cell immunoglobulin and mucin domain containing 4 (TIM4; gene Timd4 ) by MASH liver macrophages, which then drives liver fibrosis in MASH. We show that apoptotic hepatocytes accumulate in human and experimental MASH, using mice fed the fructose-palmitate-cholesterol (FPC) diet or the high-fat, choline-deficient amino acid–defined (HF-CDAA) diet. Apoptotic hepatocyte accumulation is associated with impaired efferocytosis and loss of TIM4. Administration of neutralizing anti-TIM4 antibodies or genetic deletion of Timd4 in Kupffer cells of FPC and HF-CDAA diet–fed mice decreased efferocytosis by liver macrophages, increased profibrotic activation of collagen-producing hepatic stellate cells (HSCs), and accelerated the progression to fibrotic MASH. Genetic restoration of macrophage Timd4 in FPC and HF-CDAA diet–fed MASH mice or cell therapy with TIM4 + macrophages enhanced apoptotic hepatocyte clearance and decreased HSC activation and liver fibrosis. Studies using an ex vivo macrophage HSC cross-talk model and the HF-CDAA MASH model revealed that inactivation of HSCs by efferocytosing macrophages involved macrophage reprogramming to secrete interleukin-10 (IL-10), which activated the IL-10 receptor on HSCs to dampen their profibrotic activation. These findings reveal a key process in the progression from hepatic steatosis to early MASH fibrosis and identify a mechanism-based therapeutic strategy to prevent fibrotic MASH progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisMacrophagesFatty LiverLiverPhagocytosisMembrane ProteinsAnimalsHumansApoptosisHepatocytesMiceMice, Inbred C57BLHepatic Stellate CellsMaleKupffer CellsEfferocytosis

Substanzen

TIM-4 protein, mouseMembrane ProteinsTIMD4 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Carisma Therapeutics Inc., Philadelphia, PA 19104, USA.
  • Divsion of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Precision Medicine Lab, Biological Resource Center, Department of Transfusion Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano 20122, Italy.
  • Department of Pathophysiology and Transplantation, Universitàdegli Studi di Milano, Milan 20122, Italy.
  • Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.

ORCID-Profile: Hongxue Shi, Xiaobo Wang, Christopher Sloas, Brennan Gerlach, Eui Jung Jung, Faridoddin Mirshahi, Luisa Ronzoni, Luca Valenti, Chyuan-Sheng Lin, James Montgomery, Bradley Zinker, Michael Klichinsky, Ira Tabas

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Shi, H., Wang, X., Sloas, C., Gerlach, B., Yurdagul, A., Moore, M. P., Jung, E. J., Mirshahi, F., Ronzoni, L., Sanyal, A. J., Valenti, L., Lin, C. S., Montgomery, J., Zinker, B., Klichinsky, M., & Tabas, I. (2025). Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis. Science Translational Medicine, 17(815). https://doi.org/10.1126/scitranslmed.adv2106

Vancouver

Shi H, Wang X, Sloas C, Gerlach B, Yurdagul A, Moore MP, et al. Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis. Science Translational Medicine. 2025;17(815). doi:10.1126/scitranslmed.adv2106

BibTeX
@article{Shi2025,
  author = {Shi, Hongxue and Wang, Xiaobo and Sloas, Christopher and Gerlach, Brennan and Yurdagul, Arif and Moore, Mary P and Jung, Eui Jung and Mirshahi, Faridoddin and Ronzoni, Luisa and Sanyal, Arun J and Valenti, Luca and Lin, Chyuan-Sheng and Montgomery, James and Zinker, Bradley and Klichinsky, Michael and Tabas, Ira},
  title = {Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {815},
  doi = {10.1126/scitranslmed.adv2106}
}
Kostenlos starten →